ATF4 Gene Network Mediates Cellular Response to the Anticancer PAD Inhibitor YW3-56 in Triple-Negative Breast Cancer Cells

Shu Wang1, Xiangyun Amy Chen1, Jing Hu1, Jian-kang Jiang2, Yunfei Li1, Ka Yim Chan-Salis1, Ying Gu1, Gong Chen3, Craig Thomas2, B. Franklin Pugh1, and Yanning Wang1

Abstract

We previously reported that a pan-PAD inhibitor, YW3-56, activates p53 target genes to inhibit cancer growth. However, the p53-independent anticancer activity and molecular mechanisms of YW3-56 remain largely elusive. Here, gene expression analyses found that ATF4 target genes involved in endoplasmic reticulum (ER) stress response were activated by YW3-56. Depletion of ATF4 greatly attenuated YW3-56-mediated activation of the mTORC1 regulatory genes SESN2 and DDIT4. Using the ChIP-exo method, high-resolution genomic binding sites of ATF4 and CEBPB responsive to YW3-56 treatment were generated. In human breast cancer cells, YW3-56-mediated cell death features mitochondria depletion and autophagy perturbation. Moreover, YW3-56 treatment effectively inhibits the growth of triple-negative breast cancer xenograft tumors in nude mice. Taken together, we unveiled the anticancer mechanisms and therapeutic potentials of the pan-PAD inhibitor YW3-56. Mol Cancer Ther, 14(4), 877–88. ©2015 AACR.

Introduction

Chromatin is composed of DNA and histone proteins and plays an essential role in transcriptional regulation in eukaryotic cells. Covalent modifications of DNA and histone proteins carry additional information beyond the genetic code, which is often referred as epigenetic information that impinges on gene expression to ensure normal development and cell cycle progression. Because of genetic alterations and/or aberrant expression of chromatin enzymes and regulators, deregulation of DNA and histone modifications can result in disease manifestations including cancer and neurodegenerative diseases (1–3). As such, the development of small molecules targeting chromatin factors has been pursued to restore normal gene expression patterns and to induce genes in favor of cell-cycle arrest and cell death for cancer treatment (4–7).

The peptidylarginine deiminase (PAD) family has 5 members, including PAD1, 2, 3, 4, and 6, in the human and mouse genomes (8, 9). PAD4 converts histone Arg and methyl-Arg residues to citrulline via deimination and demethylimination, respectively (10, 11). PAD4 catalyzed histone citrullination represses p53 target gene expression (e.g., p21, PUMA, and SESN2) in coordination with histone deacetylation (6, 12–14). PAD4 is also found to be a target gene of p53 and may form a negative feedback loop to regulate p53 biologic functions, such as apoptosis (15). Besides its role in gene repression, PAD4 citrullinates histone H3 Arg8 residue, thereby counteracting the function of the adjacent histone H3 Lys9 methylation and decreasing heterochromatin protein 1 binding to this methylation site (16, 17) thereby offering a mechanism underlying the proposed gene activation function of PAD4 in serving as a coactivator of Elk-1 (14).

Within the solid tumor microenvironment in vivo, cancer cells are under high levels of stresses, including metabolic stress due to the fluctuation of blood and nutrient supply, oxidative stress because of reactive oxygen species (ROS) elevation, and endoplasmic reticulum (ER) stress due to unfolded protein accumulation or a large amount of protein synthesized in the ER (18–20). The tumor suppressor p53 functions as a major node of cellular signaling network in maintaining homeostasis and guarding the genome (21, 22). Because about 50% of cancer cells lack a wild-type p53 (23), other transcription factors are expected to play an important role in regulating gene expression to cope with these cellular stresses and determine the cell fate. ATF4 (activating transcription factor 4) is well-known for its role in the ER stress response that can be induced as a result of an increase in unfolded proteins and amino acid starvation (19, 24–28). In response to the ER stress, the PERK kinase phosphorylates eIF2α, which in turn increases the translation of ATF4 (29, 30). ATF4 regulates the transcription of a cohort of downstream target genes involved in cell survival, apoptosis, autophagy, and senescence (31–34). The ultimate outcome after ATF4 activation is context-dependent, influenced by the nature of the stimulation and the cell type. In this study, we found that YW3-56 induces ER stress, thereby eliciting a robust ATF4 response.

Macroautophagy (hereafter called autophagy) is an evolutionarily conserved cellular process during which a large amount of...
cellular components is degraded in sequentially formed phagophores, autophagosomes, and autolysosomes (35–37). Autophagy is triggered as a result of starvation in many organisms and appears to be a cellular process adapted by cancer cells to cope with various stresses, such as starvation and ER stress (19, 38). Elevated autophagy facilitates cancer cell to cope with metabolic and therapeutic stresses, thus autophagy perturbation offers new opportunities for medicinal intervention in cancer treatment (6, 19, 41, 42).

We recently reported that a newly developed PAD inhibitor YW3-56 activates p53 target genes and inhibits cancer growth (6). However, it is unknown whether YW3-56 is effective in p53-mutant cancer cells. In this study, we found that YW3-56 activates ATF4 target genes that in turn regulate the mtORC1 signaling pathway. Gene expression microarray and ChIP-exo assays were performed to profile the ATF4 gene network and its biological functions. We show that YW3-56 inhibits cancer cells growth via the ER stress pathway in breast cancer MDA-MB-231 cells. Moreover, YW-56 is effective in growth inhibition of tumors derived from the triple-negative breast cancer cells in nude mice, suggesting a therapeutic potential of this inhibitor.

Materials and Methods

Cell culture, reagents, and treatment

MDA-MB-231 and its bone metastasis 1833TR cell lines were obtained from Dr. Massague (MSKCC, New York, NY) in 2011. Authentication of MDA-MB-231 and 1883TR cells was performed in 2014 using the Promega/ATCC short tandem repeat (STR) DNA fingerprinting, and the cell identity was confirmed. MDA-MB-231 and its derivative 1833TR cells were cultured in DMEM (Gibco) supplemented with 10% FBS and 1% penicillin/streptomycin in a 5% CO2 incubator at 37°C. Compounds were added when cells reached about 70% confluence for additional analyses. Concentrations and duration of YW3-56 treatment were performed as specified in this article. Other cell lines in Supplementary Fig. S1 were used for the ICP analyses only, including MCF-7, HCC38, HL-60, Jurkat, CDM1, K562, Hel, Caco-2, HT-29, H2OS, HepG2, A549, H1129, S180, and MCF-10A cells, and were obtained from HL-60, Jurkat, GDM1, K562, Hel, Caco-2, HT-29, H2OS, HepG2, A549, H1129, S180, and MCF-10A cells, and were obtained from ATCC within the last 5 years and used at early passages stored at early passages. Mouse embryonic stem J1 cells were a product of the group, purchased from C57BL/6 mice. Mouse embryonic stem J1 cells were a product of the group, purchased from MSKCC, New York, NY) in 2011.

Compounds were added when cells reached about 70% confluence for additional analyses. Concentrations and duration of YW3-56 treatment were performed as specified in this article. Other cell lines in Supplementary Fig. S1 were used for the ICP analyses only, including MCF-7, HCC38, HL-60, Jurkat, CDM1, K562, Hel, Caco-2, HT-29, H2OS, HepG2, A549, H1129, S180, and MCF-10A cells, and were obtained from HL-60, Jurkat, GDM1, K562, Hel, Caco-2, HT-29, H2OS, HepG2, A549, H1129, S180, and MCF-10A cells, and were obtained from ATCC within the last 5 years and used at early passages stored at early passages. Mouse embryonic stem J1 cells were a product of the group, purchased from C57BL/6 mice. Mouse embryonic stem J1 cells were a product of the group, purchased from MSKCC, New York, NY) in 2011.

Yeast mate pairs were released in the presence of 12 μmol/L YW3-56 or vehicle for 6 hours and then subjected to 1% formaldehyde crosslinking for 10 minutes. After being quenched with 125 mmol/L final concentration of glycine for 5 minutes, cells were harvested and washed. Sonicated chromatin was prepared by standard methods. Chromatin immunoprecipitation (ChIP) was performed with anti-ATF4 (Santa Cruz, sc-200) and anti-CEBPB (Bethyl, A302-738A) using standard ChIP methods. Lambda exonuclease treatment and library construction were performed as previously described (45). In total, 5 replicates from 3 biological experiment sets were done for each antibody following the same protocol. Sequencing was performed using Illumina HiSeq 2000 at Penn State University. Reads generated by ChIP-exo experiment were aligned to the UCSC human genome hg19 (http://genome.ucsc.edu) using BWA with default parameters (46). Uniquely aligned tags were retained and filtered to remove those from blacklist regions provided by the ENCODE project. The resulting distribution of reads was used to identify the forward (W) and reverse (C)-strand peaks using GeneTrack with sigma = 5 and exclusion zone = 10 (47, 48). The W and C peaks were paired if they were 3’ to each other and less than 60 bp apart. Because the analysis of individual replicates displays significant consistence in predicted target genes, tags from 5 replicates were merged together for final peak-pair calls. According to the normal distribution of tag counts of peak-pairs in IgG data set, we assumed that 99% of the peak-pairs, which have a tag count of less than 9 (mean ± 3 SD), is background noise. Correspondingly, peak-pairs that have a tag count of less than 9 were first removed from merged data sets of IgG, ATF4, and CEBPB. Tag counts of peak-pairs retained in each data set were still normally distributed. For reliability, less than top 1% peak-pairs—top 1,500 peak-pairs that have a tag count more than 26 from the ATF4 dataset and top 1,500 peak-pairs that have a tag count more than 27 from the CEBPB data set—were used for predicting target genes. A total of 35 peak-pairs met the criteria of tag count more than 26 from the IgG dataset were used to generate a list of unspecific antibody recognition sites.

Identification of ATF4 and CEBPB target genes and binding motifs

Binding sites identified by ChIP-exo of ATF4 (1,500 peak-pairs), CEBPB (1,500 peak-pairs), and IgG (35 peak-pairs) were assigned to the nearest RefSeq TSSs within 25 kb on either strands using the UCSC human genome hg19 annotation, yielding 589, 610, and 13 genes, respectively. By filtering away the potential unspecific targets of antibody, 579 and 607 target genes were identified for ATF4 and CEBPB, respectively. Each binding site would only be assigned to one transcription start site (TSS), whereas one TSS might be associated with multiple binding sites. Motif analyses of the top 1,500 binding locations were performed using the MEME suite.
Microarray, IPA analyses, and GSEA analyses of global gene expression changes

MDA-MB-231 cells were treated with 8 μM/L YW3-56 for 8 hours before harvesting. Control cells were mock treated with DMSO. Total RNA was extracted as described above. The Affymetrix GeneChip Human Gene 1.0 ST arrays were used. Data from all Affymetrix GeneChips were normalized and analyzed as previously described (6). Quantitative PCR of specific genes was performed using SYBR Green SuperMix (Quanta Biosciences) in the StepOnePlus Real-Time PCR System (Applied Biosystems). Primers used in quantitative PCR are listed in Supplementary Table S1. Western blot analyses were performed essentially as described previously (6). Antibodies used in Western blotting were listed in Supplementary Materials and Methods.

siRNA treatment and forced overexpression of ATF4 and CEBPB
siRNA treatment and forced overexpression of ATF4 and CEBPB

Functional enrichment analyses
Functional enrichment analyses on 579 ATF4 and 607 CEBPB putative target genes identified by ChIP-exo were performed using DAVID tools (52) to identify significantly overrepresented biologic functions defined by Gene Ontology terms. Enrichment score is used to rank the biologic significance of the gene groups.

qRT-PCR and Western blot analyses
Cells harvested from 6-well plates were washed with PBS, and total RNA was extracted using the RNeasy Mini Kit (Qiagen) following the manufacturer’s instructions. Quantitative reverse transcription PCR (qRT-PCR) was done using qScript cDNA SuperMix (Quanta Biosciences) as previously described (6). Quantitative PCR of specific genes was performed using SYBR Green SuperMix (Quanta Biosciences) in the StepOnePlus Real-Time PCR System (Applied Biosystems). Primers used in quantitative PCR are listed in Supplementary Table S1. Western blot analyses were performed essentially as described previously (6). Antibodies used in Western blotting were listed in Supplementary Materials and Methods.

Live cell imaging of mCherry-GFP-LC3
MDA-MB-231 cells were transfected with the mCherry-GFP-LC3B reporter plasmid. The transfection was performed using Lipofectamine 2000 (Invitrogen) in a 35-mm glass bottom dish according to the manufacturer’s instructions. Cells were cultured for 12 hours after transfection, before the addition of YW3-56. After incubation with YW3-56 for 12 hours, the live cell imaging was performed using an AxioSkop 40 fluorescence microscope (Carl Zeiss, Inc.) equipped with an AxioCam MRM camera and the AxioVision AC software. For transmission electronic microscopy (TEM) analyses, MDA-MB-231 cells were treated with 10 μM/L YW3-56 for 8 hours and fixed in 2% glutaraldehyde in 0.1 mol/L phosphate buffer, pH 7.4. TEM imaging was performed in the Penn State Electron Microscopy Facility.

Fluorescent and TEM microscopy
To visualize the LC3B subcellular localization, MDA-MB-231 cells were treated with 8 μM/L YW3-56 for 12 hours and fixed in 3.7% paraformaldehyde in PBS buffer containing 0.1% Triton X-100 and 0.2% NP-40, pH 7.4. Primary antibody LC3B (Cell signaling) was 1:200 diluted in PBS containing 2% BSA and 5% normal goat serum. Cells were stained with the L3CB antibody overnight at 4°C and then washed with PBST for 3 × 10 minutes and stained with Alexa488-conjugated secondary antibody to room temperature for 2 hours in the dark as previously described (11). Nuclear DNA was visualized by Hoechst staining. Imaging was obtained using an Axioskop 40 fluorescence microscope (Carl Zeiss, Inc.) equipped with an AxioCam MRM camera and the AxioVision AC software.
(Harlan Lab). After tumors achieved approximately 30 to 50 mm³, tumor-bearing mice were randomly grouped into 3 mice per group and injected with YW3-56 (12.5 mg/kg daily for 29 days, 25 mg/kg daily for 32 days, or 40 mg/kg once every 2 days for 26 days) or vehicle (10% DMSO in PBS). Tumor volume and body weight were measured daily to evaluate the antitumor activity of YW3-56. At the end point of the experiments, mice were sacrificed. Tumors and important organs (brain, lung, heart, liver, spleen, and kidney) were dissected and weighed. A section of the tumors were used for RNA and protein extraction. Tumor tissues were fixed in formalin, and hematoxylin and eosin (H&E) staining were performed using the service of the ADL (animal diagnostic laboratory) at Penn State University.

Statistics

Data for descriptive statistics analyses are presented as mean values with error bars indicating ± SD or ± SEM. Experiments are repeated, and the numbers of the biologic replicates (n) used for data analyses are indicated in the figures. The Student t test (unpaired, 2-tailed) was used to compare 2 groups of independent samples. Western blotting results are representative results from 2 or 3 independent experiments.

Results

Pan-PAD inhibitor YW3-56 inhibits histone citrullination and cell growth of p53-mutant cancer cells

YW3-56 is a structural mimic of the PAD4 substrate peptidylarginine (Supplementary Fig. S2A), and inhibits PAD4-mediated histone citrullination via covalent modification of PAD4 (Supplementary Fig. S2B–S2D). We analyzed the killing efficacy (IC50) of YW3-56 on a panel of cancer cell lines of different tissue origins and p53 status and found that YW3-56 demonstrated an IC50 below 10 μmol/L in breast cancer, leukemia, and colorectal cancer cell lines largely independent of the p53 status while low cytotoxicity to normal cells (Supplementary Fig. S1A).

Figure 1.

ER stress response genes are prominently affected in YW3-56–treated MDA-MB-231 cells. A, the IPA analyses of microarray data found canonical pathways significantly affected by YW3-56 treatment. B, GSEA assays found that gene sets important for ER protein homeostasis are enriched after YW3-56 treatment. The normalized enrichment scores (NES) and FDR are shown. Color index represents gene expression changes, and the leading edge genes are colored red. C, the expression of ATF4 target genes was significantly altered after YW3-56 treatment.
ER stress response genes are prominently activated in MDA-MB-231 cells after YW3-56 treatment

Triple-negative breast cancers lack estrogen receptor (ER), progesterone receptor (PR), and amplified Her2 for targeted therapy and have a great need for novel drug target development. YW3-56 inhibited the growth of the triple-negative breast cancer MDA-MB-231 (carrying the p53R280K mutation) and its derivative 1833 cells after bone metastasis (55). In contrast, the nontumorigenic MCF10A breast epithelial cells were not efficiently killed by YW3-56 (Supplementary Fig. S1B), indicating a therapeutic window for this compound. To analyze the molecular mechanisms, we performed gene expression microarray analyses. In total, 1,204 genes with ≥1.5-fold increase or decrease in expression were identified (P < 0.01, n = 3; Supplementary Table S2). Using 2 independent microarray data analysis tools (IPA and GSEA), we found that the ER stress/unfolded protein response (UPR) genes are significantly altered after YW3-56 treatment (Fig. 1A and B).

ATF4 is a key upstream transcription factor mediating YW3-56 response

To identify transcription factor(s) regulating YW3-56 responses, we used the upstream regulator analyses tool in IPA and identified ATF4 as a high confidence (P = 1.16 × 10⁻¹⁰) regulator of cellular response to YW3-56 (Fig. 1C). ATF4 target genes, such as DDIT4, SESN2, CEBPB, and DDIT3, were strongly induced by YW3-56 (Supplementary Table S2). Moreover, IPA
gene network analyses found that the ATF4-DDIT4-TRIB3 ($P = 1.0 \times 10^{-31}$) and the SESN2-AMPK-TORC1 ($P = 1.0 \times 10^{-28}$) gene networks have significant changes after YW3-56 treatment (Supplementary Fig. S3A and S3B; refs. 56, 57).

ATF4 is a bZIP transcription factor, which can form homodimers or heterodimers with other bZIP proteins (e.g., CEBPB) to regulate transcription (24, 58, 59). Consistent with the idea that YW3-56 triggers the ER stress and activates ATF4 target genes, ATF4 protein and the expression of its target genes (e.g., SESN2 and DDIT4) were increased after YW3-56 treatment (Fig. 2A and B). RNA interference assays found that ATF4 but not CEBPB is required for the basal and induced amount of SESN2 and DDIT4 expression (Fig. 2A and B), suggesting that ATF4 is an important mediator of YW3-56 response in MDA-MB-231 cells. Moreover, after ectopic expression of ATF4 and CEBPB, ATF4 induced the expression of SESN2, DDIT4, and DDIT3 at both protein and mRNA levels (Fig. 2C and D) whereas CEBPB had only subtle effects (Fig. 2E and F). Thus, ATF4 activates UPR genes after YW3-56 treatment, without necessarily involving CEBPB. ChIP analyses detected ATF4 binding at SESN2 and DDIT4 gene promoters after YW3-56 treatment (Supplementary Fig. S4A and S4B), suggesting that ATF4 plays a direct role in the activation of these genes.

Figure 3.

ChIP-exo identification of ATF4- and CEBPB-binding sites and recognition motifs. A, coordinate plot and density plot of ATF4- and CEBPB-binding locations within the −25 to +25 kb region of target gene promoters. B, function enrichment analysis of ATF4 and CEBPB target genes. C and D, ATF4- and CEBPB-binding motif 1 identified by MEME analyses. E and F, the frequency of ATGC in ATF4 and CEBPB motif 1 was plotted. G and H, FIMO plot analyses of 914 ATF4 motif 1 sites and 1,277 CEBPB motif 1 sites. 50-bp sequences centered on motif 1 were aligned.
ChIP-exo identification of genome-wide ATF4-binding sites after YW3-56 treatment

To address how ATF4 regulates transcription in response to YW3-56 treatment, we analyzed the genome-wide binding of ATF4 and CEBPB as a control using the newly developed high-resolution ChIP-exo method (45). Among the top 1,500 binding sites, 701 ATF4 sites and 728 CEBPB sites were mapped to the −25 to +25 kb region of RefSeq genes (based on the h19 human genome annotation; Fig. 3A). Relative enrichment and density mapping plots indicate both ATF4 and CEBPB binding sites are enriched around the TSS (Fig. 3A). The IgG ChIP-exo control samples identified 13 potential nonspecific genes. After removing nonspecific genes, we found that 579 genes have nearby ATF4-binding sites (Supplementary Table S3) and 607 genes have nearby CEBPB-binding sites (Supplementary Table S4). ATF4 candidate genes are enriched in biologic function groups, such as mRNA metabolism and ER stress response, whereas CEBPB candidate genes are involved in kinase activity regulation and cell proliferation (Fig. 3B). Furthermore, ATF4 and CEBPB have overlapping candidate genes involved in cell proliferation and transcriptional regulation.

Next, we performed motif analyses of the top 1,500 ATF4 and CEBPB binding locations using the MEME suite. Of the 1,500 ATF4-binding sites, 914 (61%) contain a canonical ATF4 motif [TGATG(C/A)AA] (Fig. 3C), whereas 1,277 of the 1,500 CEBPB-binding sites (85%) contain a canonical CEBPB motif [TTGC(A/G)(C/T)(A/C)A] (Fig. 3D). The ATGC frequency in the canonical motifs was shown for ATF4- and CEBPB-binding sites to demonstrate motif reservation (Fig. 3E and F). Sequence alignment of 50-bp DNA sequences centered on the canonical motif (hereafter called motif 1) shows the sequence features of these sites (Fig. 3G and H). Taken together, ChIP-exo provided a precise genome-wide view of ATF4 and CEBPB binding upon ER stress induction by YW3-56.

ATF4 and CEBPB candidate genes responsive to YW3-56 treatment

To analyze the effects of YW3-56 on ATF4 and CEBPB candidate genes, we queried the microarray results. After YW3-56 treatment, 73 ATF4 and 59 CEBPB candidate genes showed significant changes of gene expression (Fig. 4A and Supplementary Table S5). Sequence tag density map showed that after YW3-56 treatment, ATF4 binds much stronger at several highly inducible candidate genes, including DDIT3, DDIT4, SESN2, and CHAC1 (Fig. 4B), as well as CSTF2T, GEMIN7, HSFA9, and WDR36 (Supplementary Fig. S5A). In the top 1,500 ATF4-binding sites, 914 (61%) contain a canonical ATF4 motif [TGATG(C/A)AA] (Fig. 3C), whereas 1,277 of the 1,500 CEBPB-binding sites (85%) contain a canonical CEBPB motif [TTGC(A/G)(C/T)(A/C)A] (Fig. 3D). The ATGC frequency in the canonical motifs was shown for ATF4- and CEBPB-binding sites to demonstrate motif reservation (Fig. 3E and F). Sequence alignment of 50-bp DNA sequences centered on the canonical motif (hereafter called motif 1) shows the sequence features of these sites (Fig. 3G and H). Taken together, ChIP-exo provided a precise genome-wide view of ATF4 and CEBPB binding upon ER stress induction by YW3-56.

Table 1. Functional categories of ATF4-associated genes

<table>
<thead>
<tr>
<th>Response to unfolded protein</th>
<th>Transcription</th>
<th>Metabolism</th>
<th>Oxidative stress</th>
<th>Others</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHAC1</td>
<td>ARETL</td>
<td>ADORA2B</td>
<td>SESN2</td>
<td>BS510 cilium formation</td>
</tr>
<tr>
<td>DDI3</td>
<td>BRF2</td>
<td>AGPAT9</td>
<td>TXNL4B</td>
<td>CTF27 RNA processing</td>
</tr>
<tr>
<td>DNAJB1</td>
<td>CBX4</td>
<td>ALOXE3</td>
<td>TXNRI1</td>
<td>GEMIN7 RNA processing</td>
</tr>
<tr>
<td>DNAJB5</td>
<td>CEBPB</td>
<td>DFPYSL2</td>
<td>DNA damage response</td>
<td>WDR36 RNA processing</td>
</tr>
<tr>
<td>HERPUD1</td>
<td>JDP2</td>
<td>GFTPT1</td>
<td>DDIT4</td>
<td>CLC1 intracellular transport</td>
</tr>
<tr>
<td>HSPA5</td>
<td>JHDMD</td>
<td>GPT2</td>
<td>DNA damage response</td>
<td>CRISPLD2 extracellular matrix</td>
</tr>
<tr>
<td>PPP1R15A</td>
<td>KCDT14</td>
<td>MOC53</td>
<td>GADD45A</td>
<td>FMNL1 cell adhesion</td>
</tr>
<tr>
<td>TRIB3</td>
<td>MKX</td>
<td>MTHFD2</td>
<td>TIPIN</td>
<td>MLPH cell motility</td>
</tr>
<tr>
<td>WIP1I</td>
<td>NCOA7</td>
<td>PCK2</td>
<td>DNA damage response</td>
<td>TUF1 extracellular matrix</td>
</tr>
<tr>
<td>XBPI1</td>
<td>NFIL3</td>
<td>SLC3A2</td>
<td>Cell signaling</td>
<td>CD50 unknown</td>
</tr>
<tr>
<td></td>
<td>RUNX2</td>
<td>SLC7A1</td>
<td>DNA damage response</td>
<td>CCDC9 unknown</td>
</tr>
<tr>
<td></td>
<td>STOX1</td>
<td>VDR</td>
<td>EEVI2A</td>
<td>FAM102A unknown</td>
</tr>
<tr>
<td></td>
<td>TSC22D3</td>
<td>WARS</td>
<td>GDF15</td>
<td>FAM27C unknown</td>
</tr>
<tr>
<td></td>
<td>ZFP69B</td>
<td>ALDH2</td>
<td>RGMB</td>
<td>RHBD2 unknown</td>
</tr>
<tr>
<td></td>
<td>ZNF479</td>
<td>ASB1</td>
<td>RND3</td>
<td>TES unkonwn</td>
</tr>
<tr>
<td></td>
<td>ZNF682</td>
<td></td>
<td></td>
<td>DGAP1-AS1 ncRNA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>MALAT1 lincRNA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NBR2 ncRNA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SNORD83B lincRNA</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SNORD96A unknown</td>
</tr>
</tbody>
</table>
contrast, ATF4 binding at EVI2A and RUNX2 does not increase (Supplementary Fig. S5B), suggesting that ATF4 prefers certain targets sites for binding after YW3-56 treatment. These 73 ATF4 associated and YW3-56 inducible genes are involved in diverse biologic functions, such as response to UPR, transcription, and metabolism (Table 1).

YW3-56 induces ER stress and activates ATF4 through the PERK–eIF2α signaling cascade

ATF4 translation is activated by PERK-mediated eIF2α phosphorylation during ER stress response (Fig. 5A; refs. 29, 30). We found that the PERK protein was upshifted [an indicator of PERK phosphorylation and activation (ref. 28)] in YW3-56 concentration–dependent manner at 4 hours after drug treatment (Fig. 5B). Furthermore, the phosphorylation of eIF2α at the PERK target site Ser51 was significantly increased with a concomitant increase of the ATF4 protein (Fig. 5B). Thus, YW3-56 induced UPR and activated the PERK–eIF2α–ATF4 signaling cascade. After PERK depletion with siRNAs, YW3-56 did not induce eIF2α Ser51 phosphorylation and the accumulation of ATF4 (Fig. 5C). Concomitantly, SESN2 induction by YW3-56 was attenuated after PERK depletion (Fig. 5D). Above results suggest that PERK activity
ATF4 Mediates Cellular Response to YW3-56

is important for YW3-56–induced activation of ATF4 and its downstream target genes. SESN2 and DDIT4 are upstream inhibitors of the mTORC1 kinase. With the SESN2- and DDIT4–transfected cells showed large numbers of autophagic vesicles denoted by yellow arrows. Note the disappearance of mitochondria. B, immunostaining of LC3B (green) in control and YW3-56–treated cells, noting the increased LC3B staining and LC3B speckles in YW3-56–treated cells. DNA (blue) was stained by Hoechst. C, YW3-56 inhibits autophagosome maturation to autolysosomes as measured by live cell imaging using the mCherry-GFP-LC3B reporter protein based on the quenching of the GFP signals by the acidic environment within autolysosomes. D, percentages of autophagosomes and autolysosomes identified in control and YW3-56–treated cells based on the GFP and RFP fluorescent signals. After YW3-56 treatment, the number of speckles with both RFP and GFP signals (representing autolysosomes) was increased from about 56% (n = 19) to about 98% (n = 23), *, P < 0.002. E, effect of YW3-56 on autophagy regulatory protein LC3B and p62/SQSTM1.

Figure 6. YW3-56 induces cell death by affecting autophagy flux. A, TEM images of control MDA-MB-231 cells showing normal cellular structures with mitochondria denoted by green arrows. In contrast, YW3-56–treated MDA-MB-231 cells showed large numbers of autophagic vesicles denoted by yellow arrows. Note the disappearance of mitochondria. B, immunostaining of LC3B (green) in control and YW3-56–treated cells, noting the increased LC3B staining and LC3B speckles in YW3-56–treated cells. DNA (blue) was stained by Hoechst. C, YW3-56 inhibits autophagosome maturation to autolysosomes as measured by live cell imaging using the mCherry-GFP-LC3B reporter protein based on the quenching of the GFP signals by the acidic environment within autolysosomes. D, percentages of autophagosomes and autolysosomes identified in control and YW3-56–treated cells based on the GFP and RFP fluorescent signals. After YW3-56 treatment, the number of speckles with both RFP and GFP signals (representing autolysosomes) was increased from about 56% (n = 19) to about 98% (n = 23), *, P < 0.002. E, effect of YW3-56 on autophagy regulatory protein LC3B and p62/SQSTM1.

The ATF4 siRNA slowed growth of 1833 cells (Supplementary Fig. S7A). However, MB-231 cells after bone metastasis (55). Depletion of ATF4 led to proteins in 1833 cells that are derived from the parental MDA-MB-231 cells and 4EBP1 was detected after thapsigargin treatment (Supplementary Fig. S6A), suggesting that mTORC1 inhibition is a general cellular event following ER stress. Above results favor a model that ATF4 downstream target gene expression in turn affects autophagy regulation by ER stress, these proteins facilitate YW3-56–mediated cell killing.

YW3-56–mediated cell death features mitochondria depletion and autophagy perturbation

Treatment of MDA-MB-231 cells with YW3-56 increased the staining of propidium iodide (PI) and Annexin V—2 cell death markers while decreased the staining of MitoTracker Deep Red—a fluorescent dye detecting the mitochondria membrane potential (Supplementary Fig. S8A). Furthermore, the YW3-56–treated cells did not show an increase in PARP cleavage, a canonical apoptosis marker (Supplementary Fig. S8B). Compared with control cells (Fig. 6A), YW3-56–treated cells showed an increase in autophagic vesicles with a concomitant decrease in mitochondria (Fig. 6A). Moreover, immunostaining showed an increased in LC3B vesicles (Fig. 6B). Using the RFP-GFP-LCB reporter to indicate the pH of autophagic vesicles in live cells, an inhibition of autophagosomes to autolysosomes conversion after YW3-56 treatment was detected (Fig. 6C and D). Moreover, the autophagy-mediated degradation of LC3B-II and the p62/SQSTM1 proteins was inhibited after YW3-56 treatment (Fig. 6E). Taken together, these results...
suggest that the autophagy flux was blocked after YW3-56 treatment.

YW3-56 inhibits the growth of MDA-MB-231–derived tumors in nude mice

To test whether YW3-56 is effective in inhibiting the growth of xenograft tumors derived from the triple-negative breast cancer cells, we used the 1833 cells that are derived from the parental MDA-MB-231 cells after bone metastasis (55). Three experiments with different dosage of YW3-56 were performed, and the percentage of tumor growth inhibition was tallied (Fig. 7A). At the 12.5 mg/kg dosage, a binary response to YW3-56 was observed: 2 tumors showed little response, whereas the other 4 tumors showed significant growth inhibition (Fig. 7B). The images of dissected tumors showed the size and morphology difference of these tumors (Fig. 7B). In tumors that showed growth inhibition (4L and 5L), an increase in the expression of YW3-56–inducible genes (e.g., SENS2 and DDIT4) was detected by qRT-PCR (Table 2). In contrast, in the tumor with no drug response (6L), these genes were largely unaltered (Table 2), suggesting an effective YW3-56 concentration did not achieve in the tumors without response.

When YW3-56 was used at 25 mg/kg body weight daily or 40 mg/kg body weight once every 2 days, significant tumor growth inhibition was detected (Fig. 7A). At the 40 mg/kg dosage, we found that all tumors (n = 6) grew much slower after drug treatment (Fig. 7C). The images of dissected tumors showed a decrease in tumor size after YW3-56 treatment (Fig. 7D). Analyses of gene expression in these xenograft tumors found an increase in

Table 2. Effects of YW3-56 on gene expression in xenograft tumors

<table>
<thead>
<tr>
<th>Treatment</th>
<th>PBS</th>
<th>YW3-56 (12.5 mg/kg)</th>
<th>PBS</th>
<th>YW3-56 (40 mg/kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genes</td>
<td></td>
<td>4L</td>
<td>5L</td>
<td>6L</td>
</tr>
<tr>
<td>SESN2</td>
<td>1 ± 0.22</td>
<td>5.4</td>
<td>83.2</td>
<td>1.5</td>
</tr>
<tr>
<td>DDIT4</td>
<td>1 ± 0.03</td>
<td>19.8</td>
<td>3.9</td>
<td>1.4</td>
</tr>
<tr>
<td>GADD45</td>
<td>1 ± 0.08</td>
<td>5.0</td>
<td>5.1</td>
<td>0.7</td>
</tr>
<tr>
<td>PUMA</td>
<td>1 ± 0.22</td>
<td>2.6</td>
<td>116.8</td>
<td>1.1</td>
</tr>
<tr>
<td>DDIT3</td>
<td>1 ± 0.14</td>
<td>1.8</td>
<td>63.7</td>
<td>1.9</td>
</tr>
</tbody>
</table>

Figure 7. Growth inhibition effects of YW3-56 on xenograft tumors of the triple-negative breast cancer 1833 cells. A, box plot showing the relative tumor weight (control tumors normalized to 100%, n = 6) obtained from three xenograft experiments with different dosage of YW3-56. **, P < 0.002. B, images of tumors in control and daily 12.5 mg/kg YW3-56 treatment groups. C, growth curves of tumors after treatment without or with 40 mg/kg YW3-56 once every 2 days. D, images of tumors without or with 40 mg/kg YW3-56 treatment once every 2 days. E, representative pathology hematoxylin and eosin (H&E) staining of the control and YW3-56–treated tumors. Yellow arrows denote blood vessels.
the expression of YW3-56 inducible genes (Table 2). Pathologic analyses found less red blood cells and less fat tissues at the tumor surface after YW3-56 treatment (Fig. 7E), suggesting that YW3-56 affects multiple biologic aspects of tumor growth in mice.

Discussion

In summary, we identified ATF4 as an essential transcription factor mediating the expression of mTOR upstream regulatory genes DDIT4 and SESN2 after YW3-56 treatment. The ATF4–SESN2/DDIT4–mTOR signaling circuit offers a molecular link between YW3-56 and the mTORC1 signaling pathway. High-resolution mapping of ATF4- and CEBPβ-binding sites using the ChiP-exo method revealed the gene networks and biologic pathways they regulate. YW3-56 induces the ER stress response and inhibits the autophagy flux in the triple-negative breast cancer cells. These cellular pathways synergize to induce cell growth inhibition and cell death. Finally, we showed that YW3-56 is effective in the inhibition of triple negative p53-mutant breast tumor growth in a xenograft model. Overall, YW3-56 offers a potential new therapeutic agent by altering gene expression in cancer cells.

Cancer cells explore the various survival mechanisms to cope with environmental stresses and become additive to these pathways. Conditioning the ER stress by inhibiting protein degradation (e.g., bortezomib) is capable of pushing cancers over the cliff of cell death (60). Likewise, inhibitors of autophagy can inhibit cancer growth (19). In our work, YW3-56 perturbs multiple processes required for cancer growth, including the ER stress induction and autophagy inhibition. Given these pleiotropic effects, it is not surprising that YW3-56 inhibits the growth of tumor cells with diverse tissue origins and genetic background.

ATF4 is a basic leucine zipper (bZIP) type of transcription factor that can be induced by various stress conditions, including hypoxia, ER stress, and starvation (24, 25, 61, 62). The depletion of ATF4 significantly decreased YW3-56–induced SESN2 and DDIT4 expression at both protein and mRNA levels, whereas forced expression of ATF4 was sufficient for the SESN2 and DDIT4 expression increase, suggesting that ATF4 is both required and sufficient in mediating the expression of SESN2 and DDIT4 after YW3-56 treatment. During the process to prepare our work for publication, a report showed that protease inhibitor drugs neflinavir and bortezomib induces SESN2 via ATF4 (63), raising an interesting possibility that SESN2 is a common effector linking ER stress drugs and the mTORC1 signaling pathway.

Disclosure of Potential Conflicts of Interest

B.F. Pugh is Founder/Co-Owner of Peconic, Inc. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions

Conception and design: S. Wang, B.F. Pugh, Y. Wang Development of methodology: S. Wang, X.A. Chen, Y. Li, C. Thomas, B.F. Pugh Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): S. Wang, X.A. Chen, J. Hu, Y. Cui, B.F. Pugh, Y. Wang Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): S. Wang, X.A. Chen, J. Hu, Y. Li, C. Thomas, B.F. Pugh, Y. Wang Writing, review, and/or revision of the manuscript: S. Wang, X.A. Chen, C. Thomas, B.F. Pugh, Y. Wang Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): S. Wang, K.Y. Chan-Salis, Y. Gu, Y. Wang Study supervision: G. Chen, C. Thomas, Y. Wang

Grant Support

This work was supported by a NIH/NCI grant R01 CA136856 and a PBCC grant to Y. Wang. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Acknowledgments

The authors thank Drs. Joan Massagué, Yibin Kang, and Andrea Mastro for cell lines and Drs. Terje Johansen and Tso-Pang Yao for reagents. They also thank laboratory members and members of the Center for Eukaryotic Gene Regulation for comments and helpful discussions. They thank the Penn State University Microscopy and Cytometry Facility and the Genomics Core Facility for technical help and thank Dr. Ying Gu from Penn State University for help with microscope imaging.

Received January 5, 2015; accepted January 12, 2015; published OnlineFirst January 22, 2015.

References


24. Wang et al. Published OnlineFirst January 22, 2015; DOI: 10.1158/1535-7163.MCT-14-1093-T.

25. Wang et al. Downloaded from mct.aacrjournals.org on February 14, 2018. © 2015 American Association for Cancer Research.
Molecular Cancer Therapeutics

ATF4 Gene Network Mediates Cellular Response to the Anticancer PAD Inhibitor YW3-56 in Triple-Negative Breast Cancer Cells

Shu Wang, Xiangyun Amy Chen, Jing Hu, et al.

Mol Cancer Ther 2015;14:877-888. Published OnlineFirst January 22, 2015.

Updated version Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-14-1093-T

Supplementary Material Access the most recent supplemental material at:
http://mct.aacrjournals.org/content/suppl/2015/01/22/1535-7163.MCT-14-1093-T.DC1

Cited articles This article cites 62 articles, 20 of which you can access for free at:
http://mct.aacrjournals.org/content/14/4/877.full#ref-list-1

E-mail alerts Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
Permissions To request permission to re-use all or part of this article, use this link http://mct.aacrjournals.org/content/14/4/877. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.